

Silco Pharmaceuticals Limited
Un-Audited Financial Statements (3rd Quarter)
For the Period from 01 July, 2021 to 31 March, 2022

Silco Pharmaceuticals Limited

Statement of Financial Position

As at March 31, 2022

Particulars	Notes	Amount in Taka	
		31 March 2022	30 June 2021
Assets			
Non Current Assets		1,625,074,723	1,643,359,449
Property, Plant and Equipment	3.00	1,387,017,154	1,241,146,404
Right of Use Assets	4.00	4,957,704	7,619,739
Capital Work In Progress	5.00	233,099,865	394,593,305
Current Assets		1,098,848,423	1,052,230,886
Inventories	6.00	450,343,570	449,452,463
Trade Receivables	7.00	403,075,120	390,532,203
Advance, Deposits and Prepayments	8.00	143,027,076	139,804,640
Cash and Cash Equivalents	9.00	60,306,178	53,031,144
Investment In Share	10.00	42,096,480	19,410,437
Total Assets		2,723,923,145	2,695,590,335
Shareholders Equity and Liabilities			
Shareholders Equity		2,281,506,776	2,268,018,123
Share Capital	11.00	1,038,070,000	1,038,070,000
Unrealized Gain/Loss on Marketable Securities		(6,497,110)	(369,919)
Retained Earnings	12.00	1,249,933,886	1,230,318,041
Non-Current Liabilities		146,452,041	144,611,002
Lease Liability (Non Current Portion)		2,226,329	4,112,546
Deferred Tax Liability	13.00	144,225,712	140,498,457
Current Liabilities		295,964,328	282,961,209
Trade Payable	14.00	10,900,061	16,154,859
Lease Liability (Current Portion)	15.00	2,860,213	3,773,307
Payable to IPO Applicants		184,728	185,021
Creditors & Accruals	16.00	9,295,783	10,471,189
Liability for WPPF	17.00	9,834,388	10,735,596
Dividend Payable (Unclaimed)	18.00	2,297,592	1,234,260
Current Tax Liability	19.00	260,591,563	240,406,977
Total Shareholders Equity and Liabilities		2,723,923,145	2,695,590,335
Net Asset Value (NAV) per Share	27.00	21.98	21.85

The annexed notes form an integral part of these financial statements.

সাইফ হাভেল

Chairman

Managing Director

Director

Company Secretary

Chief Financial Officer






SIGNED IN TERMS OF OUR ANNEXED REPORT OF EVEN DATE

Date: Dhaka
May 16, 2022

Silco Pharmaceuticals Limited
Statement of Profit or Loss and other Comprehensive Income
For the period ended March 31, 2022

Particulars	Notes	Amount in Taka			
		July 2021 to Mar. 2022	July 2020 to Mar. 2021	Jan. 2022 to Mar. 2022	Jan. 2021 to Mar. 2021
Turnover	20.00	500,864,767	550,025,920	179,853,256	188,735,248
Less: Cost of Goods Sold	21.00	329,319,981	365,754,817	112,153,805	118,630,681
Gross Profit		171,544,785	184,271,103	67,699,451	70,104,567
Less: Operating Expenses	22.00	69,623,053	76,998,419	22,565,856	25,360,518
Profit from Operation		101,921,733	107,272,684	45,133,595	44,744,049
Less: Financial Expenses	23.00	214,477	446,823	61,083	175,826
Less: Financial Expenses (Lease)		431,347	-	123,629	-
Non-operation Income	24.00	11,133,223	4,505,188	2,172,876	2,058,954
Profit before Contribution to WPPF		112,409,132	111,331,049	47,121,759	46,627,177
Less: Workers' Profit Participation/Welfare Fund (WPPF)		5,352,816	5,301,479	2,243,893	2,220,342
Profit before Income Tax		107,056,316	106,029,570	44,877,866	44,406,835
Less: Provision for Income Tax	25.00	23,911,841	26,507,393	10,604,886	11,101,709
Current Tax		20,184,586	20,013,913	8,924,654	7,710,557
Deferred Tax		3,727,255	6,493,480	1,680,232	3,391,152
Net Profit after Tax (Transferred to CE)		83,144,475	79,522,178	34,272,980	33,305,126
Other Comprehensive Income:					
Unrealized Gain/Loss on Investment		(6,127,192)	-	1,143,506	-
Total Comprehensive income		77,017,283	79,522,178	35,416,487	33,305,126
Earnings per Share (EPS)	26.00	0.80	0.77	0.33	0.32

The annexed notes form an integral part of these financial statements.

 Chairman
 Managing Director
 Director
 Company Secretary
 Chief Financial Officer

Date: Dhaka
May 16, 2022

Silco Pharmaceuticals Limited
Statement of Changes In Equity
For the period ended March 31, 2022

(Amount in Taka)

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2021	1,038,070,000	(369,919)	1,230,318,041	2,268,018,123
Net Profit/(Loss) during the period	-	-	83,144,475	83,144,475
Declared 10% Cash Dividend			(63,528,630)	(63,528,630)
Unrealized Gain/Loss on Marketable Shares	-	(6,127,192)	-	(6,127,192)
Balance as on March 31, 2022	1,038,070,000	(6,497,110)	1,249,933,886	2,281,506,776

Statement of Changes in Equity
For the period ended March 31, 2021

(Amount in Taka)

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2020	1,038,070,000	-	1,208,429,254	2,246,499,254
Declared 10% Cash Dividend			(62,758,630)	(62,758,630)
Net Profit/(Loss) during the period	-	-	79,522,178	79,522,178
Balance as on March 31, 2021	1,038,070,000	-	1,225,192,802	2,263,262,802

সাইলকো ফার্মাসিউটিক্যালস লিমিটেড

Chairman

Managing Director

Director

Company Secretary

Chief Financial Officer

Date: Dhaka
May 16, 2022

Silco Pharmaceuticals Limited

Statement of Cash Flows

For the period ended March 31, 2022

Particulars	Notes	Amount in Taka	
		July 2021 to March 2022	July 2020 to Mar. 2021
A. Cash Flows from Operating Activities			
Cash received from Customers	31.00	488,321,850	562,305,025
Cash received from Non-operating income		4,657,209	4,505,188
Cash Paid to Suppliers	32.00	(234,485,772)	(239,760,756)
Cash Paid to Employees	33.00	(56,727,505)	(62,584,512)
Cash Paid to Others	34.00	(57,909,872)	(63,974,145)
Financial Expenses		(214,477)	-
Income Tax Paid		(7,829,591)	(14,377,013)
Net cash flows from operating activities		135,811,841	186,113,786
B. Cash Flows from Investing Activities			
Acquisition of Property, Plant & Equipment		(25,919,228)	(2,129,328)
Cash Received/Payments to/from FDR		-	73,149,692
Cash Payments for Capital Work-in-Progress		(14,584,110)	(271,972,720)
Gain on Investment		6,476,014	-
Investment in Share		(28,813,235)	-
Net cash used in investing activities		(62,840,558)	(200,952,355)
C. Cash Flows from Financing Activities			
Refund to IPO Applicants		(293)	-
Financial Expenses (Lease)		(431,347)	-
Principle payment (Lease)		(2,799,311)	-
Cash dividend paid		(62,465,298)	(59,041,046)
Net Cash used for financing activities		(65,696,249)	(59,041,046)
D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)		7,275,034	(73,879,615)
E. Cash and Cash Equivalents at the beginning of the period		53,031,144	101,969,302
F. Cash and Cash Equivalents at the end of the period (D+E)		60,306,178	28,089,687
Net Operating Cash Flows Per Share (NOCFPS)	28.00	1.31	1.79

সাইকো ফার্মাসিউটিক্যালস লিমিটেড

Chairman

Managing Director

Director

Company Secretary

Chief Financial Officer

Date: Dhaka
May 16, 2022